Title
The histone variant H2A.Bbd is enriched at sites of DNA synthesis
Date Issued
02 June 2014
Access level
open access
Resource Type
journal article
Author(s)
Sansoni V.
Rajan M.
Schmidt A.
Bönisch C.
Thomae A.W.
Staege M.S.
Hake S.B.
Cardoso M.C.
Imhof A.
Technische Universität Darmstadt
Publisher(s)
Oxford University Press
Abstract
Histone variants play an important role in shaping the mammalian epigenome and their aberrant expression is frequently observed in several types of cancer. However, the mechanisms that mediate their function and the composition of the variant-containing chromatin are still largely unknown. A proteomic interrogation of chromatin containing the different H2A variants macroH2A.1.2, H2A.Bbd and H2A revealed a strikingly different protein composition. Gene ontology analysis reveals a strong enrichment of splicing factors as well as components of the mammalian replisome in H2A.Bbd-containing chromatin. We find H2A.Bbd localizing transiently to sites of DNA synthesis during S-phase and during DNA repair. Cells that express H2A.Bbd have a shortened S-phase and are more susceptible to DNA damage, two phenotypes that are also observed in human Hodgkin's lymphoma cells that aberrantly express this variant. Based on our experiments we conclude that H2A.Bbd is targeted to newly synthesized DNA during replication and DNA repair. The transient incorporation of H2A.Bbd may be due to the intrinsic instability of nucleosomes carrying this variant or a faster chromatin loading. This potentially leads to a disturbance of the existing chromatin structure, which may have effects on cell cycle regulation and DNA damage sensitivity. © 2014 The Author(s) 2014.
Start page
6405
End page
6420
Volume
42
Issue
10
Language
English
OCDE Knowledge area
Genética, Herencia
Scopus EID
2-s2.0-84903154988
PubMed ID
Source
Nucleic Acids Research
ISSN of the container
0305-1048
DOI of the container
10.1093/nar/gku303
Sponsor(s)
German Research Foundation (DFG, SFB TR5) (S.B.H.) [DFG Ca 198/7 and DFG GRK1657/1 to M.C.C.], Center for Integrated Protein Science Munich (CIPSM) (S.B.H. and A.I.); European Union (Stategra) (A.I.); Marie Curie Fellowship [INTEGER 214902 to V.S.]; European Union [EpiGeneSys 257082 to V.S.]; Peter-Escher-Foundation for children with cancer (M.S.S.). Source of open access funding: EpiGeneSys 257082. Conflict of interest statement. None declared.
Sources of information:
Directorio de Producción Científica
Scopus